Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.640 +0.040 (+0.53%)
Official Closing Price Updated: 8:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Congressional Leaders Want Studies to be Conducted on Mental Health Benefits of Psychedelics
Via Investor Brand Network
Topics Law Enforcement
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
Via Investor Brand Network
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
Archaeologists Believe Hidden Andean Passageways Were Most Likely Used During Psychedelic Rituals
Via Investor Brand Network
New Study Finds That Probiotics May Be Useful in Fight Against Depression
Via Investor Brand Network
NJ Senate President Introduces Psilocybin Legalization Bill Containing Home-Cultivation Provision
Via Investor Brand Network
Topics Cannabis
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Why More Attention Needs to Be Paid to Paternal Mental Health
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval
Via Investor Brand Network
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
New Netflix Series to Explore the Use of Psychedelics for Mental Health
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results
Via Investor Brand Network
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Advances in Precision Medicine Boost Research on Psychedelics
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics
Via Investor Brand Network
What You Should Know About Ego Death
Via Investor Brand Network
World’s Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a... 
Via FinancialNewsMedia
WHO Wants Climate Change Efforts to Prioritize Mental Health
Via Investor Brand Network
Topics Climate Change
Four Key Takeaways from the Catalyst Summit in Canada
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial
Via Investor Brand Network
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
New Study Suggests That MDMA May Decrease Fear, Boost PTSD Treatment
Via Investor Brand Network
New Research Finds That Individuals Prefer Guide with Personal Psilocybin Experience
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study
Via Investor Brand Network
Cybin Acquires DMT Clinical Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.